Integration of Wearable Sensor Devices Into a Single System to Predict the Onset of Sepsis (IRHIS)
調査の概要
状態
条件
詳細な説明
This is a prospective clinical performance study involving ICU patients at risk of developing sepsis. The study will assess the integration of portable sensor devices into the CPC telemonitoring platform for the collection and visualization of physiological and biomarker data.
The CPC12S device will collect vital physiological parameters, including electrocardiography, oxygen saturation, non-invasive blood pressure, respiratory rate, heart rate, body position, and physical activity. A CPC temperature and humidity sensor will be used for continuous monitoring of body temperature and humidity. In addition, the IDRO investigational sweat lactate sensor will be integrated into the system to collect sweat lactate data.
The study will be conducted in phases. In the first phase, patients will be monitored using the CPC12S device together with the temperature and humidity sensor. In the second phase, patients will be monitored using the CPC system, the temperature and humidity sensor, and the IDRO sweat lactate sensor.
All patients will be monitored for up to 48 hours. The collected data will be analyzed together with clinical information recorded by healthcare professionals. The primary objective is to support prediction of sepsis onset by integrating data from the CPC12S device, the CPC temperature/humidity sensor, and the IDRO sweat lactate sensor. Secondary objectives include completing the integration of the IDRO sensor into the CPC system, validating the IDRO sweat lactate measurements against standard clinical blood lactate measurements, and developing an algorithm based on device-recorded and clinical data for sepsis prediction.
The data collected in this study will not be used to guide clinical decisions during the study. Medical care and clinical decisions will remain under the responsibility of the hospital medical team according to standard clinical practice.
研究の種類
入学 (推定)
段階
- 適用できない
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adult patients aged 18 years or older.
- Patients admitted to the intensive care unit who are at risk of developing sepsis.
- Patients with one or more relevant risk factors for sepsis, including pre-existing medical conditions, invasive medical devices, recent procedures or conditions, active infections, clinical risk factors, or prolonged ICU/hospital stay.
- Signed informed consent.Exclusion Criteria:
- Inability or unwillingness to provide informed consent or comply with study requirements.
- ICU stay shorter than 6 hours.
- Damaged tattoos, bare skin, recent scar tissue, inflammation, infection, skin barrier alteration, serous or bloody discharge, or metal plates/nails at the area where the Macroduct Advanced system and IDRO device will be placed.
- Patients admitted to the ICU with already diagnosed sepsis.
- Patients participating in other clinical studies.
- Moribund patients or patients with very short life expectancy.
- Patients with do-not-resuscitate status at admission.
- Patients with implanted devices such as an implanted defibrillator, implanted neurostimulator, implanted pacemaker, or implanted ECG monitor.
- Patients in whom short-term interference between the Macroduct device and clinical monitoring cannot be accepted.
- Patients with a history of epilepsy or seizures.
- Pregnant patients or patients who may be pregnant.
- Patients with previous adverse reactions to electrotherapy.
- Patients who present adverse reactions during the first sampling with the Macroduct device.
- Patients for whom the procedure is contraindicated for medical reasons according to the physician's decision.
- Patients with known sensitivity or allergy to pilocarpine nitrate, or any medical contraindication to pilocarpine administration.
- Patients in environments with flammable anesthetics or oxygen-enriched environments.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：非ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：CPC12S + Temperature/Humidity Sensor
Participants will be monitored using the CPC12S telemonitoring device together with the CPC temperature and humidity sensor.
Data will include physiological parameters, body temperature, and humidity during ICU monitoring.
|
The CPC12S telemonitoring system will be used together with the CPC temperature and humidity sensor to collect physiological parameters, body temperature, and humidity data from ICU patients during the monitoring period.
|
|
実験的：CPC12S + Temp/Humidity + IDRO Sensor
Participants will be monitored using the CPC12S telemonitoring system together with the CPC temperature and humidity sensor and the investigational IDRO sweat lactate sensor.
Data will include physiological parameters, temperature, humidity, and sweat lactate measurements.
|
The CPC12S telemonitoring system will be used together with the CPC temperature and humidity sensor to collect physiological parameters, body temperature, and humidity data from ICU patients during the monitoring period.
The investigational IDRO sweat lactate sensor will be used to collect sweat lactate measurements.
The sensor will be integrated with the CPC system for data transmission, visualization, and analysis.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area under the receiver operating characteristic curve (AUC-ROC) of the integrated sensor-based model for prediction of sepsis onset
時間枠：Up to 48 hours of patient monitoring
|
The primary outcome is the predictive performance of the integrated sensor-based model for identifying sepsis onset in ICU patients.
The model will use data collected from the CPC12S telemonitoring system, the CPC temperature/humidity sensor and, where applicable, the IDRO sweat lactate sensor.
Sepsis onset will be determined by the clinical diagnosis recorded by the treating medical team and assessed according to Sepsis-3 criteria.
Predictive performance will be reported as the area under the receiver operating characteristic curve (AUC-ROC).
|
Up to 48 hours of patient monitoring
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Correlation between IDRO sweat lactate measurements and standard blood lactate measurements
時間枠：Up to 48 hours of patient monitoring
|
The correlation between sweat lactate values measured by the IDRO sensor and blood lactate values measured as part of routine ICU clinical practice will be assessed using Pearson or Spearman correlation coefficients.
|
Up to 48 hours of patient monitoring
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 101160941
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。